SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2026 / Cilt: 46 Sayı: 3

Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması

Muhammed Sezgin0000-0003-2589-9668
Merve Aydın0000-0002-1522-6083
Faruk Karakeçili0000-0002-7368-7187
Aytekin Çıkman0000-0001-9259-7091
Barış Gülhan0000-0002-2605-1282
Yusuf Kemal Arslan0000-0003-1308-8569
Pages
479–487
Publication Date
2019-09-16
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Çalışmamızın amacı bruselloz hastalarında ve kontrol grubunda ADMA düzeyinin araştırılmasıdır.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: Asimetrik dimetilarginin (ADMA), nitrik oksit sentazın (NOS) ana endojen inhibitörüdür.
📊
Key Findings & Data:NOS, konak savunmasında ve vasküler yapının sürdürülmesinde önemli rol oynamaktadır.
💡
Conclusion & Impact:Çalışmamızın amacı bruselloz hastalarında ve kontrol grubunda ADMA düzeyinin araştırılmasıdır.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Asimetrik Dimetilarjinin · bruselloz

Özet

Amaç: Asimetrik dimetilarginin (ADMA), nitrik oksit sentazın (NOS) ana endojen inhibitörüdür. NOS, konak savunmasında ve vasküler yapının sürdürülmesinde önemli rol oynamaktadır. Yüksek ADMA düzeylerinin endoteldis fonksiyonu ile ilişkili olduğu ve çeşitli hastalıklarda rol aldığı gösterilmiştir. Brucellaspp.’nin neden olduğu zoonoz bir hastalık olan bruselloz, vaskülopati olarak kendini gösterebilmektedir. Ancak, bruselloz ile ADMA arasındaki ilişki ile ilgili yeterli veri bulunmamaktadır. Çalışmamızın amacı bruselloz hastalarında ve kontrol grubunda ADMA düzeyinin araştırılmasıdır.

🔖

Cite This Article

Sezgin, M., Aydın, M., Karakeçili, F., Çıkman, A., Gülhan, B., Arslan, Y. K. (2019). Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması. Dicle Tıp Dergisi, Cilt: 46 Sayı: 3, 479–487. https://doi.org/10.5798/dicletip.620502

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (29)

  1. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005; 10: 14-23.
  2. Böger RH. The emerging role of asymmetric dimethyarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59: 824-33.
  3. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005; 10: 11-7.
  4. Sitar ME, Kayacelebi AA, Beckmann B, Kielstein JT, Tsikas D. Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015; 47: 1983-93.
  5. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005; 10: 73-81.
  6. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethlyarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel). 2017; 9: 92.
  7. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003; 4: 41-51.
  8. Gwida M, Al Dahouk S, Melzer F, et all. Brucellosis – regionally emerging zoonotic disease? Croat Med J. 2010; 51: 289-95.
  9. El-Koumi MA, Afify M, Al-Zahrani SH. A prospective study of brucellosis in children: relative frequency of pancytopenia. Mediterr J Hematol Infect Dis. 2013; 5: e2013011.
  10. Dede G, Dede O, Kapmaz M, Haykır Solay A, Utangaç M. Two cases of brucellosis epididymo-orchitis. Dicle Med J. 2015; 42: 80-82.
  11. Ulu-Kilic A, Metan G, Alp E. Clinical presentations and diagnosis of brucellosis. Recent Pat Antiinfect Drug Discov. 2013; 8: 34-41.
  12. Dizbay M, Hizel K, Kilic S, et all. Brucella peritonitis and leucocytoclastic vasculitis due to Brucella melitensis. Braz J Infect Dis. 2007; 11: 443-44.
  13. Karahocagil MK, Aslan M, Ceylan MR, et all. Serum myeloperoxidase activity and oxidative stress in patients with acute brucellosis. Clin Biochem. 2012; 45: 733-6.
  14. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med. 2005; 2: e264.
  15. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008; 14: 2613-8.
  16. Weis M, Kledal TN, Lin KY, et all. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004; 109: 500-5.
  17. Karakecili F, Cikman A, Aydin M, Gulhan B. Asymmetrical dimethylarginine levels in Hepatitis B virus-positive patients. Ann Lab Med. 2018; 38: 446-9.
  18. Kurz K, Teerlink T, Sarcletti M, et all. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral theraphy. Antivir Ther. 2012; 17: 1021-7.
  19. Baranyi A, Meinitzer A, Putz-Bankuti C, et all. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection. Psychosom Med. 2014; 76: 197-207.
  20. Mengeloglu Z, Sünnetcioglu M, Tosun M, et al. High asymmetric dimethylaginine (ADMA) levels in patients with brucellosis. Inflammation. 2014; 37: 127-31.
  21. Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet’s disease. Ann Clin Lab Sci. 2006; 36: 449-54.
  22. Ferrero MC, Bregante J, Delpino MV, et al. Proinflammatory response of human endothelial cells to Brucella infection. Microbes Infect. 2011; 13: 852-61.
  23. Aydemir S, Eren H, Tekin IO, et all. Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm. 2010; 2010: 685903.
  24. Sunnetcioglu M, Mengeloglu Z, Baran AI, et all. Asymmetric dimethylarginine levels in patients with cutaneous anthrax: a laboratory analysis. Ann Clin Microbiol Antimicrob. 2014; 13: 12.
  25. Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et all. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One. 2014; 9: e90541.
  26. Parlak M, Akbayram S, Doğan M, et al. Clinical manifestations and laboratory findings of 496 children with brucellosis in Van, Turkey. Pediatr Int. 2015; 57: 586-9.
  27. Buzgan T, Karahocagil MK, Irmak H, et all. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis. 2010; 14: 469-78.
  28. Tanir G, Tufekci, SB, Tuygun N. Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatr Int. 2009; 51: 114-9.
  29. Dede G, Dede O, Kapmaz M, Haykır Solay A, Utangaç M. Two cases of brucellosis epididymo-orchitis. Dicle Med J. 2015; 42: 80-82.